Mankind Pharma Highlights Rising Kidney Disease Risk on World Kidney Day

Why It Matters

CKD’s hidden nature and massive treatment shortfall pose a public‑health crisis, and heightened awareness can reduce morbidity and alleviate pressure on India’s strained transplant system.

Key Takeaways

• CKD affects ~138 million Indians, ~10% worldwide
• Only 6% of India's transplant demand met annually
• Mankind Pharma urges regular BP, sugar, kidney tests
• Diabetes, hypertension drive India's rising kidney disease rates
• Early screening can prevent up to 90% unnoticed kidney loss

Pulse Analysis

Chronic kidney disease has emerged as a silent epidemic, affecting roughly one in ten adults worldwide and an alarming 138 million Indians. The condition often progresses without overt symptoms, allowing up to 90 percent of renal function to deteriorate before patients notice any change. Contributing factors such as rising diabetes prevalence, uncontrolled hypertension, high‑salt diets, and sedentary lifestyles exacerbate the risk, making early detection through simple blood pressure, glucose and creatinine tests a critical public‑health priority.

India’s kidney care infrastructure faces a stark mismatch between demand and supply. While an estimated 200,000 transplants are needed each year, only about 13,500 procedures are performed, representing less than six percent of the required volume. The organ donation rate remains below one donor per million people, far trailing developed nations and highlighting systemic barriers in donor registration, awareness, and logistics. This shortfall not only drives up treatment costs but also forces many patients onto costly dialysis regimens, straining both families and the healthcare system.

Mankind Pharma’s World Kidney Day campaign seeks to bridge the awareness gap by promoting routine health checks and lifestyle modifications. By encouraging the public to monitor blood pressure, blood sugar, and kidney function, the initiative aligns with medical recommendations that early screening can slow disease progression and improve outcomes. The campaign also reinforces the role of pharmaceutical companies in public‑health education, potentially influencing policy discussions around preventive care, screening programs, and organ donation incentives, thereby contributing to a more proactive approach to kidney health in India.